While a previous study by Greinacher’s team has shown no cross-reactivity of platelet-activating antibodies isolated from VITT patients with the coronavirus spike protein (and only a few out of 200 patients recovered from COVID-19 reacting weakly with PF4) [104], they now show in a recent preprint close proximity between PF4 molecule, platelets, and adenovirus hexon capsid protein-positive staining particles. This evidence concerns the gene PF4 and COVID-19.